University Of Pecs
- Address
- lock Available on a paid plan
Skin and Connective Tissue Diseases and Oncodermatology
At the University Of Pecs Department of Dermatology, Venerology and Oncodermatology, clinical research in skin and connective tissue diseases focuses on inflammatory and autoimmune conditions, along with difficult-to-treat skin disorders and skin cancers. The studies are designed to test new therapies, assess symptom control, and support longer-term treatment safety.
- Alopecia areata research exploring whether a new treatment can improve hair regrowth in children
- Atopic dermatitis and hidradenitis suppurativa trials evaluating symptom relief and treatment effectiveness
- Psoriasis studies comparing emerging options for moderate to severe disease, including special-area involvement
- Lupus erythematosus research focused on improving disease control and long-term safety of therapy
- Cutaneous squamous cell carcinoma and melanoma trials assessing new approaches for advanced skin cancer
Overall, this research area combines autoimmune dermatology with oncodermatology, reflecting a strong interest in both chronic inflammatory skin disease and cancer care.
Immune System Diseases and Immune System Processes
Clinical trials at this site also cover a broad range of immune system diseases, with an emphasis on conditions driven by abnormal immune activity. The research aims to better understand disease mechanisms while evaluating therapies that may reduce flares, improve symptoms, and offer more durable control.
- Systemic lupus erythematosus studies testing new options for active disease
- IgG4-related disease research examining ways to prevent relapse after initial treatment
- Systemic sclerosis trials looking at improvement in signs, symptoms, and disease impact
- Dermatomyositis studies evaluating whether novel treatment can reduce disease activity
- Autoimmune disease research supporting broader understanding of immune-driven inflammation
These studies reflect a strong focus on immunology and on finding more effective, better-tolerated treatments for complex systemic conditions.
Musculoskeletal Diseases and Systemic Inflammatory Disorders
Research in musculoskeletal diseases at the site includes inflammatory conditions that affect joints, muscles, and connective tissues. The clinical trials are centered on improving disease control, easing pain and stiffness, and helping patients maintain daily function.
- Axial spondyloarthritis studies assessing whether a new therapy can improve signs and symptoms
- Dermatomyositis trials focused on reducing inflammation and improving muscle-related outcomes
- Systemic sclerosis research examining broader effects on mobility and disease burden
- Immune-mediated connective tissue disease studies aimed at better symptom management
This work highlights the site’s interest in rheumatology-related research and in therapies that may improve long-term quality of life for people with chronic inflammatory disease.
Eye Diseases
At University Of Pecs, the eye diseases portfolio includes research into retinal conditions that can affect vision and daily functioning. The main goal is to evaluate new treatment approaches that may improve ocular outcomes and expand options beyond standard care.
- Diabetic macular edema studies assessing safety, tolerability, and visual benefit of a new treatment approach
- Retinal disease research aimed at improving control of fluid-related eye damage
These trials reflect a practical focus on ophthalmology, especially conditions where better treatment options could help preserve sight.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Biogen Idec Research Limited1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Of Pecs
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | Incyte Corp. | Phase II | Not Yet Recruiting | Oct 2023 | Mar 2026 |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Upadacitinib | 3 | Unknown | 2019-01-09 | 2023-11-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
